Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-13

Study Completion Date

2027-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Crohn's disease (CD) (\> 200,000 patients in France) is a chronic inflammatory disease that can lead to progression of intestinal destruction and impaired quality of life. Despite the widespread use of biotherapies, intestinal resections remain frequent (50% of patients over time). Unfortunately, surgery is not curative since 75% of patients experienced post-endoscopic operative recurrence (POR) (i.e., recurrence of ulcerations) during the first year after surgery. Prevention of endoscopic POR (defined as a Rutgeerts index ≥ i2) is essential because endoscopic POR is highly predictive of clinical POR (i.e., recurrence of CD-related symptoms): \> 40% and \> 80% within 5 years for a Rutgeerts index ≥ i2 or ≥ i3, respectively. The recommended management is to start treatment after surgery to avoid endoscopic POR, and to perform a colonoscopy at 6 months (M6) with therapeutic escalation if endoscopic POR. Despite anti-TNF or ustekinumab treatment, the endoscopic POR rate remains high (30-40% at M6) leading to \> 40% clinical POR despite therapeutic escalation (90 mg/4 weeks with ustekinumab) potentially due to late therapeutic escalation. Innovative strategies are therefore needed to prevent endoscopic POR, such as the use of fecal calprotectin, a non-invasive biomarker associated with endoscopic CD activity. We have previously demonstrated that its variation between surgery and M3 allows for a value at M3 predictive of endoscopic POR at M6. In this study, we hypothesize, for the first time, that a strategy integrating fecal calprotectin measurement at M3 with earlier therapeutic escalation (M3 vs M6) in case of abnormal value or kinetics could decrease the rate of endoscopic POR at M6.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease

NCT06299631

Crohn's Disease

COMPLETED

Impact of the Fecal Flora Transplantation on Crohn's Disease

NCT02097797

Crohn's Disease

COMPLETED NA

Postoperative REcurrence and DynamICs of T Cell Subsets in Crohn's Disease

NCT02770495

Crohn Disease

COMPLETED PHASE3

Prediction and Close Monitoring of Postoperative Recurrence by Intestinal Ultrasound After Ileocecal Resection in Crohn's Disease Patients

NCT05713409

Crohn Disease

UNKNOWN

Comparison of Endoscopy and Diffusion-weighted Enterography-MRI for the Diagnosis of Crohn's Disease Recurrence Following Ileocolic Resection: a Pilot Study

NCT02867540

Crohn's Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, open-label, multicenter, two-arm, randomized, controlled clinical trial evaluating innovative versus standard care in patients with Crohn's disease. All eligible patients will be offered the study consecutively by the principal investigator or any other co-investigator declared on the study.

At the pre-inclusion visit (W-4 to W0 before inclusion), after verification of inclusion and non-inclusion criteria and obtaining consent, a laboratory assessment and an abdominal ultrasound (if participating in the DESTINY-echo ancillary study) will be prescribed (pre-biotherapy assessment, CRP) as well as a fecal calprotectin measurement.

After reverifying the inclusion and non-inclusion criteria, at the inclusion visit (W0), patients will be randomized between the two study arms (standard arm vs. active arm). Randomization will be stratified by center and number of risk factors. The results of this randomization will be shared with both the investigator and the patient.

The reference arm will be based on daily practice, i.e., regular monitoring (weeks 0 and 24) with fecal calprotectin testing at week 10, the results of which will be unknown for the duration of the study but may be disclosed upon patient exit, and with ustekinumab intensification at 6 months based on endoscopy results. In the active arm, in the event of an abnormal fecal calprotectin test result (\> 100 μg/g at week 10 or a variation between week 0 and week 10 of \> 50 μg/g), the investigator will be informed by electronic alert, and treatment intensification at week 12 will be required. Fecal calprotectin testing will be standardized and performed using the same test in all patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease (CD) Ileocolic Resection Post-endoscopic Operative Reccurence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active arm

Early dosage of fecal calprotectin at 3 months

Group Type ACTIVE_COMPARATOR

Early faecal calprotectin dosage

Intervention Type BIOLOGICAL

An early dosage of faecal calprotectin will be done for the active arm group.

Standard arm

Standard dosage of fecal calprotectin at 6 months

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Early faecal calprotectin dosage

An early dosage of faecal calprotectin will be done for the active arm group.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with an established diagnosis of CD according to ECCO guidelines
* Adult Crohn's disease (age ≥ 18 years)
* Having undergone ileal, colonic, or ileocolonic resection without residual macroscopic lesions
* With an anastomosis that can be reached by ileocolonoscopy
* With at least one of the following risk factors for endoscopic POR: active smoking, previous intestinal resection (before the current resection), length of resected small bowel \> 30 cm, fistulizing phenotype (B3 according to the Montreal classification), exposure to at least two biotherapies before surgery
* No contraindication to ustekinumab treatment
* Patient capable of giving consent
* Patient covered by the French healthcare system

Exclusion Criteria

* Permanent stoma
* Total colectomy
* Uncontrolled postoperative infectious complication
* Pregnant or breastfeeding women: a pregnancy test will be performed for women of childbearing age
* Refusal to participate in the study
* Persons deprived of their liberty by judicial or administrative decision
* Minors
* Vulnerable protected adults (under guardianship, curatorship, or legal protection)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anthony Buisson

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Clermont-Ferrand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.